Table 4.
Ongoing and completed clinical trials exploring dsRNA as adjuvant.
| No. | Intervention | Condition | Phase | Status | NCT Number |
|---|---|---|---|---|---|
| 1 | Viral Vector Vaccine Encoding Avian Influenza H5N1 Hemagglutinin Protein and dsRNA Adjuvan (ND1.1) | Avian influenza | Phase 1 | Completed | NCT01335347 |
| 2 | Adenoviral-Vector Based Seasonal Influenza A Vaccine and dsRNA Adjuvant (VXA-A1.1) | Influenza | Phase 1 Phase 1 Phase 2 |
Completed Completed Completed |
NCT01688297 NCT03121339 NCT02918006 |
| 3 | Adenoviral-Vector Based Norovirus Vaccine Expressing GI.1 VP1 and dsRNA Adjuvant (VXA-G1.1-NN) | Norovirus gastroenteritis | Phase 1 Phase 1 (high dose) |
Completed Completed |
NCT03125473 NCT02868073 |
| 4 | Adenoviral-Vector Based RSV F Protein Vaccine and dsRNA Adjuvant (VXA-RSV-f) | Respiratory syncytial virus (RSV) | Phase 1 | Completed | NCT02830932 |
| 5 | Adenoviral-Vector Based Vaccine Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant (VXA-CoV2-1) | COVID-19 | Phase 1 Phase 2 Phase 2 (w/Isotretinoin) Phase 3 (w/Isotretinoin) |
Active Recruiting Not yet recruiting Not yet recruiting |
NCT04563702 NCT05067933 NCT04577378 NCT04353180 |
| 6 | Hiltonol (poly ICLC—Poly(I:C) stabilized with polylysine and carboxymethylcellulose) | Healthy volunteers | Phase 1 | Completed | NCT01012700 |
| 7 | NY-ESO-1 protein; poly-ICLC; montanide | Melanoma | Phase 1 Phase 2 |
Completed Active |
NCT01079741 NCT02334735 |